<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01242098</url>
  </required_header>
  <id_info>
    <org_study_id>004/11</org_study_id>
    <nct_id>NCT01242098</nct_id>
  </id_info>
  <brief_title>Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management</brief_title>
  <acronym>Fos/Ser_switch</acronym>
  <official_title>Retrospective, Real-life Observational, Matched Cohort Evaluation of the Effectiveness of BDP/FOR (Fostair® 100/6) and FP/SAL (Seretide® 125) in Patients Switching From Seretide to Fostair in UK Primary Care Asthma Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research in Real-Life Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Research in Real-Life Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether beclomethasone dipropionate / formoterol&#xD;
      (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to&#xD;
      fluticasone dipropionate / salmeterol (FP/SAL; Seretide® 125) in matched asthma patients&#xD;
      switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared&#xD;
      with patients not switched.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exacerbation rate</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>Where an exacerbation is defined as:&#xD;
(i) Asthma-related&#xD;
Hospital attendance / admissions OR&#xD;
Accident &amp; Emergency (A&amp;E) attendance OR&#xD;
(ii) Use of oral steroids.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exacerbation control (a composite proxy measure)</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>Controlled:&#xD;
Absence of:&#xD;
(i) Asthma-related:&#xD;
Hospital attendance or admission&#xD;
A&amp;E attendance, OR&#xD;
Out of hours consultations, OR&#xD;
Out-patient department attendance&#xD;
(ii) GP consultations for lower respiratory tract infection&#xD;
(iii) Prescriptions for acute courses of oral steroids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment success 1</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>(i) Exacerbation control&#xD;
AND&#xD;
(ii) No change in therapeutic regimen:&#xD;
≥50% increase in ICS dose relative to IPD dose, and/or&#xD;
Change in ICS/LABA drug within class, and/or&#xD;
Change in delivery device, and/or&#xD;
Use of additional (defined as not received during baseline year) therapy as defined by: theophylline, leukotriene receptor antagonists (LTRAs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma hospitalisations</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>Definite: Hospitalisations coded with an asthma read code&#xD;
Definite + Probable: Hospitalisations with an asthma read code + uncoded hospitalisations occurring within a 7-day window (either side of the hospitalisation date) of an asthma read code</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with ICS/LABA therapy</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>Compliance calculation based on prescription refills and (where possible) compliance questionnaire data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of reliever medication</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>average daily dosage during outcome year. Outcome SABA usage will be categorised within ranges used to match baseline SABA use to optimise matching of the treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of therapeutic regimen.</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>Mean healthcare costs (drug costs + consultation, admission costs, etc - total and respiratory-related) per patient recorded during the outcome year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma-related / respiratory hospitalisations</measure>
    <time_frame>one year outcome period</time_frame>
    <description>Definite: Hospitalisations coded with a lower respiratory code&#xD;
Definite + Probable: Hospitalisations with an asthma read code + uncoded hospitalisations occurring within a 7-day window (either side of the hospitalisation date) of a lower respiratory read code</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Thrush</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>Identified as:&#xD;
(i) Topical oral anti-fungal prescriptions, and / or&#xD;
(ii) Coded for oral candidiasis</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">137</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Fostair switch cohort</arm_group_label>
    <description>Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and switch to Fostair</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seretide continuation cohort</arm_group_label>
    <description>Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and continue on Seretide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed dose combination salmeterol / fluticasone</intervention_name>
    <description>Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy</description>
    <arm_group_label>Seretide continuation cohort</arm_group_label>
    <other_name>FP/SAL; Seretide® 125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed-dose combination beclometasone dipropionate / formoterol</intervention_name>
    <description>Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy</description>
    <arm_group_label>Fostair switch cohort</arm_group_label>
    <other_name>BDP/FOR; Fostair® 100/6</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving ICS/LABA therapy as FP/SAL (Seretide® 125) who, at an index prescription&#xD;
        date (IPD) receive a routine asthma review* and either:&#xD;
&#xD;
        (i) Switched to BDP/FOR (Fostair®)at same or lower BDP-equivalent ICS dose;&#xD;
&#xD;
        OR,&#xD;
&#xD;
        (ii) Continues on FP/SAL (Seretide® 125) for the duration of the outcome period at the same&#xD;
        or lower BDP-equivalent ICS dose prescribed at baseline.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged:&#xD;
&#xD;
               -  18-60 years:&#xD;
&#xD;
               -  61-80 years who are never-smokers&#xD;
&#xD;
          -  Evidence of asthma:&#xD;
&#xD;
               -  a diagnostic code for asthma, or&#xD;
&#xD;
               -  ≥2 prescriptions for asthma at different points in time during the prior year&#xD;
&#xD;
          -  Baseline FP/SAL therapy:&#xD;
&#xD;
               -  ≥2 prescription for ICS/LABA therapy as FP/SAL (Seretide® 125).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any chronic respiratory disease other than asthma&#xD;
&#xD;
          -  Are receiving maintenance oral steroid therapy during baseline period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Optimum Patient Care</name>
      <address>
        <city>Cawston</city>
        <state>Norfolk</state>
        <zip>NR10 4FE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.optimumpatientcare.org</url>
    <description>Optimum Patient Care is the Research in Real Life's sister company (a social enterprise organisation)</description>
  </link>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>November 11, 2010</study_first_submitted>
  <study_first_submitted_qc>November 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Research in Real-Life Ltd</investigator_affiliation>
    <investigator_full_name>Alison Chisholm</investigator_full_name>
    <investigator_title>David Price</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Combination therapy</keyword>
  <keyword>Primary care management</keyword>
  <keyword>Switch</keyword>
  <keyword>ICS/LABA</keyword>
  <keyword>Fostair</keyword>
  <keyword>Seretide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

